Under the category of the Innovative Medicines are listed out-licensing offers for the medicines with patent protection or other types of exclusivity. Members of Farmavita.net are invited to publish their out-licensing offers in this Category.
I have two promising novel classes of anticancer drugs with first in class attributes available for in licensing.
The Non Proteolytic Proteasome Inhibitor demonstrated a Proteasome inhibition through a novel mechanism/target. This compound is currently at the lead generation stage.
POC : In-vitro cytotoxicactivity on human cancer cells